TriangleNCT03430011 · OUTCOME
Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Score on a Scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and visit 24 month
What was measured
QLQ-MY20 includes 20 questions across four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.
Analysis population: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
Groups in this outcome
Phase 2 600 x 10^6 Cells
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
| Group | Source count |
|---|---|
| Phase 2 600 x 10^6 Cells | 4 |
Reported measurements
Disease Symptoms
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 2 600 x 10^6 Cells | 0.00 | 0.00 | Not reported | Not reported | Not reported |
Side Effects of Treatment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 2 600 x 10^6 Cells | 6.11 | 3.98 | Not reported | Not reported | Not reported |
Future Perspectives
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 2 600 x 10^6 Cells | 11.11 | 9.07 | Not reported | Not reported | Not reported |
Body Image
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 2 600 x 10^6 Cells | 16.67 | 33.33 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.00
- value
- 0.00
- title
- Disease Symptoms
- categories
- measurements
- group Id
- OG000
- spread
- 3.98
- value
- 6.11
- title
- Side Effects of Treatment
- categories
- measurements
- group Id
- OG000
- spread
- 9.07
- value
- 11.11
- title
- Future Perspectives
- categories
- measurements
- group Id
- OG000
- spread
- 33.33
- value
- 16.67
- title
- Body Image
- denoms
- counts
- group Id
- OG000
- value
- 4
- units
- Participants
- description
- QLQ-MY20 includes 20 questions across four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.
- dispersion Type
- Standard Deviation
- groups
- description
- JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
- id
- OG000
- title
- Phase 2 600 x 10^6 Cells
- param Type
- MEAN
- population Description
- All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol
- reporting Status
- POSTED
- time Frame
- Baseline and visit 24 month
- title
- Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ-MY20) in Phase 2
- type
- SECONDARY
- unit Of Measure
- Score on a Scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice